Within-Drug Comparison of Glitazone Exposure and Sulfonylurea Exposure in Myocardial Infarction Cases and Matched Controls who received Metformin as First-Line Drug Therapy.

*CI denotes confidence interval.
†The current cumulative exposure period is the number of months of continuous exposure prior to the event (for cases) or matched index date (controls). Cumulative current exposure includes continuous drug use up until the index date. Exposure that was accumulated prior to any lapse in therapy of greater than 90 days was defined as past exposure.
‡Odds ratios have been adjusted for matching variables (age in 5-year groupins, sex, family income band in $5,000 dollar increments, number of family members, and existence of supplemental coverage).
§Odds ratios have been adjusted for (in addition to the matching variables) time since initiation of metformin, the following within 5 years of the index date: congestive heart failure, angiography, coronary artery bypass graft, percutaneous transluminal angioplasty, ischemic stroke, transient ischemic attack, angina, prior AMI, renal disease; and the following within one year of index: Romano comorbidity score, exposure to nitrates, statins, angiotensen II converting enzyme inhibitors or receptor blockers, thiazide diuretics, calcium channel blockers, beta blockers, clopidogrel, digoxin, warfarin, insulin, and past use of metformin, glitazones and sulfonylureas.